Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemophilia b | D002836 | — | D67 | 2 | — | 4 | 1 | 8 | 15 |
Hemophilia a | D006467 | EFO_0007267 | D66 | 3 | — | 3 | 1 | 7 | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | — | — | 1 | 2 |
Hemostatic disorders | D020141 | — | — | 1 | — | — | — | — | 1 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | — | — | 1 | 1 |
Hemorrhagic disorders | D006474 | — | D69.9 | — | — | — | — | 1 | 1 |
Coagulation protein disorders | D020147 | — | — | — | — | — | — | 1 | 1 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Thrombosis | D013927 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Eftrenonacog alfa |
INN | eftrenonacog alfa |
Description | Alprolix (eftrenonacog alfa) is a fusion protein pharmaceutical. Eftrenonacog alfa was first approved as Alprolix on 2016-05-12. It has been approved in Europe to treat hemophilia b. |
Classification | Fusion protein |
Drug class | Fc fusion protein |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594598 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 02E00T2QDE (ChemIDplus, GSRS) |